US, China Extend Trade Truce to Jan. 10 Ahead of Trump-Xi Summit 
Russian Envoy Dmitriev Heads to US for Ukraine Talks 
US Northeast Airports Resume Operations After Telecom Outage Disrupts Thousands of Flights 
US Dollar Hits Two-Month High as Fed Rate Hike Bets Rise 
Oil Prices Surge as U.S.-Iran Diplomacy Hopes Fade 
Oil Prices Ease as Iran Tensions Clash With Diplomacy Hopes 
Anthropic’s Claude Discovers CRISPR-Like Enzyme System 
Microsoft Stock Upgraded as Stifel Sees Stronger Azure Growth 
Telix to Acquire Germany’s ITM in $1.65 Billion Radiopharma Deal 
Wall Street Surges as Meta Leads AI Rally, Oil Prices Fall 
SoftBank Raises $11.1 Billion in Bond Sale to Fund OpenAI Investment 
Asian Currencies Muted as Dollar Firms Ahead of Trump-Xi Summit 
Petrobras Joins Brazil’s New Diesel Subsidy Program 
Meta Connect Spotlights Camera-Free Smart Glasses Amid Privacy Concerns 
Meta Unveils Muse Charm AI Device, Expands Smart Glasses Lineup 
Add as a preferred source on Google
Celltrion, a South Korean pharmaceutical company, formulated a COVID-19 antibody treatment, and it is reportedly ready to deliver the drug to the United States and Europe. With its new treatment, the company has now made the world’s third drug for coronavirus.
Now it is likely to enter the European and U.S. markets before this year ends, as per The Korea Herald. This information was revealed in a report that was released on Monday, Aug. 23.
Lee Dong Geon, an analyst at Shinhan Investment, said that Celltrion will be applying for the issuance of emergency use authorization for its Regkirona COVID-19 antibody treatment. It is hoped that the US Food and Drug Administration will approve this drug that is also called the CT-P59 for EUA.
Moreover, it was predicted that it would not be long until Celltrion’s Regkirona is approved. In fact, it may be out in the U.S. market as early as the fourth quarter of this year. As for the EU market, it was estimated that it could obtain regulatory approval from the Europen Medicine Agency before October since it is already under review.
Apparently, once Celltrion succeeded in rolling out Regkirona in the U.S. and Europe, the company’s position in the pharmaceutical business will surely improve, and this will be felt and observed in the coming months.
In any case, Rekirona is an antibody treatment for coronavirus, and it is the first drug to be developed by Celltrion. It already received a green light from South Korea, Indonesia, and recently, in Brazil. The pharma firm said that as soon as the EMA gives its approval, it will immediately ship the drug to the EU.
Celltrion said that this treatment could shorten the number of treatment days for patients with COVID-19. What’s more, it could also prevent the condition of patients from getting severe.
Meanwhile, as soon as the news of Celltrion’s possible shipment of Regkirona to major markets in the world, Pulse News reported that the company’s shares soared, gaining 6.77 percent to close at ₩284,000 or around $241.97 on Kospi. It was added that it finished 8.21 percent higher and Celltrion Healthcare also went up by 7.94 percent.
